Targovax AS is registered on the NOTC-list
Targovax AS is registered on the NOTC-list from June 16th, 2014, with ticker code TRVX. The company has issued 9 429 404 shares, each at par value NOK 0.10. All shares are registered in VPS with ISIN code NO 001 0689326. Based on the most recent capital increase, June 4th, 2014, where the shares were […]
Nordic Nanovector: Betalutin™ granted Orphan Designation in Europe
Oslo Cancer Cluster member Nordic Nanovector`s lead product candidate Betalutin™ has been granted orphan designation for treatment of follicular lymphoma in Europe by the European Medicines Agency (EMA) and the European Commission (EC). Orphan designation for Betalutin™ will provide the company several advantages, including reduced costs related to the clinical development program, as well as […]
Cambridge-report shows high number of oncology publications per capita in Norway
MBA students from University of Cambridge did a benchmarking of international oncology clusters this spring on behalf of the Oslo Cancer Cluster. Please download an excerpt of the report here. Key findings; • Norway has a high number of oncology publications per capita • The entrepreneurial culture in Norway represents untapped commercial potential • There […]
Targovax successfully completes a 70 MNOK financing
Immunotherapy specialist Targovax announces completion of a 70 MNOK financing, mainly from new investors. The share issue was significantly oversubscribed. CEO Hanne M Kristensen states; “The capital increase of 70 MNOK will make us able to continue developing Targovax’s pipeline of immunotherapies targeting RAS mutated cancer forms, and also gives us a strong position to […]
Vaccibody AS and Phibro Animal Health Corporation enter into Development and License Agreement
The Norwegian vaccine company Vaccibody and Phibro Animal Health Corporation (Nasdaq:PAHC), a global animal health and mineral nutrition company, have signed a global exclusive license agreement which grants Phibro and its affiliates the right to develop, market and sell novel vaccines for the poultry market using the Vaccibody platform technology. Under the agreement, Phibro and […]
Lytix presents at ASCO
Lytix Bioharma presents data at ASCO from the first LTX-315 clinical trial. Sunday June 1st Lytix Biopharma presents results from the first Phase I clinical study with LTX-315 at the 50th annual ASCO (American Society of Clinical Oncology). The results are presented as a poster at the ‘Developmental Therapeutics – Immunotherapy Poster Session’. The poster […]
